- Home
- KRC vs MMED Comparison
KRC vs MMED Comparison
Compare KRC & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | MMED |
|---|---|---|
| Founded | 1947 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | KRC | MMED |
|---|---|---|
| Price | $38.74 | $16.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $37.36 | $22.56 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 04-27-2026 | 06-03-2026 |
| Dividend Yield | ★ 6.57% | N/A |
| EPS Growth | ★ 31.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,112,667,000.00 | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $2.13 | $10.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.36 | $10.65 |
| 52 Week High | $45.03 | $17.86 |
Technical Indicators
Market Signals| Indicator | KRC | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 60.33 |
| Support Level | $37.45 | $14.70 |
| Resistance Level | $39.82 | N/A |
| Average True Range (ATR) | 0.85 | 0.89 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 30.63 | 58.72 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About MMED MiniMed Group Inc. Common Stock
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.